Suppr超能文献

评估药剂师主导的药物评估,以确定患有癌症的门诊老年患者中药物使用过多和潜在不适当用药的流行程度和相关因素。

Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer.

机构信息

Ginah Nightingale and Emily Hajjar, Jefferson School of Pharmacy; Kristine Swartz and Andrew Chapman, Thomas Jefferson University Hospital; and Jocelyn Andrel-Sendecki, Thomas Jefferson University, Philadelphia, PA.

出版信息

J Clin Oncol. 2015 May 1;33(13):1453-9. doi: 10.1200/JCO.2014.58.7550. Epub 2015 Mar 23.

Abstract

PURPOSE

The use of multiple and/or inappropriate medications in seniors is a significant public health problem, and cancer treatment escalates its prevalence and complexity. Existing studies are limited by patient self-report and medical record extraction compared with a pharmacist-led comprehensive medication assessment.

PATIENTS AND METHODS

We retrospectively examined medication use in ambulatory senior adults with cancer to determine the prevalence of polypharmacy (PP) and potentially inappropriate medication (PIM) use and associated factors. PP was defined as concurrent use of five or more and less than 10 medications, and excessive polypharmacy (EPP) was defined as 10 or more medications. PIMs were categorized by 2012 Beers Criteria, Screening Tool of Older Person's Prescriptions (STOPP), and the Healthcare Effectiveness Data and Information Set (HEDIS).

RESULTS

A total of 248 patients received a geriatric oncology assessment between January 2011 and June 2013 (mean age was 79.9 years, 64% were women, 74% were white, and 87% had solid tumors). Only 234 patients (evaluated by pharmacists) were included in the final analysis. Mean number of medications used was 9.23. The prevalence of PP, EPP, and PIM use was 41% (n = 96), 43% (n = 101), and 51% (n = 119), respectively. 2012 Beers, STOPP, and HEDIS criteria classified 173 occurrences of PIMs, which were present in 40%, 38%, and 21% of patients, respectively. Associations with PIM use were PP (P < .001) and increased comorbidities (P = .005).

CONCLUSION

A pharmacist-led comprehensive medication assessment demonstrated a high prevalence of PP, EPP, and PIM use. Medication assessments that integrate both 2012 Beers and STOPP criteria and consider cancer diagnosis, prognosis, and cancer-related therapy are needed to optimize medication use in this population.

摘要

目的

老年人中多种和/或不适当药物的使用是一个重大的公共卫生问题,而癌症治疗则加剧了其普遍性和复杂性。与药剂师主导的综合药物评估相比,现有的研究受到患者自我报告和病历提取的限制。

患者和方法

我们回顾性地检查了患有癌症的门诊老年患者的药物使用情况,以确定多药治疗(PP)和潜在不适当药物(PIM)使用的患病率以及相关因素。PP 定义为同时使用五种或更多但少于十种药物,而过量多药治疗(EPP)定义为使用十种或更多药物。PIM 按 2012 年 Beers 标准、老年人处方筛选工具(STOPP)和医疗保健效果数据和信息集(HEDIS)进行分类。

结果

2011 年 1 月至 2013 年 6 月期间,共有 248 名患者接受了老年肿瘤学评估(平均年龄为 79.9 岁,64%为女性,74%为白人,87%患有实体瘤)。只有 234 名患者(由药剂师评估)被纳入最终分析。使用的药物平均数量为 9.23。PP、EPP 和 PIM 使用的患病率分别为 41%(n=96)、43%(n=101)和 51%(n=119)。2012 年 Beers、STOPP 和 HEDIS 标准共分类了 173 例 PIM,分别有 40%、38%和 21%的患者存在 PIM。与 PIM 使用相关的因素是 PP(P<.001)和合并症增多(P=0.005)。

结论

药剂师主导的综合药物评估显示 PP、EPP 和 PIM 使用的患病率较高。需要进行药物评估,综合考虑 2012 年 Beers 和 STOPP 标准,并考虑癌症诊断、预后和癌症相关治疗,以优化该人群的药物使用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验